BACKGROUND: The use of human papillomavirus (HPV) vaccines has been universally
approved for women from age 12 to 25 years, but those older than 16 years receive no …

We evaluated the cost‐effectiveness of HPV16/18 vaccination for girls aged 12 years in The
Netherlands in addition to cervical cancer screening. For this purpose, we developed a …

Introduction Vaccination against human papillomavirus (HPV) is considered the most
effective strategy to protect women from cervical cancer. Three HPV vaccines are currently …

Abstract Background In the Netherlands, low cervical cancer incidence and mortality rates
might limit the cost-effectiveness of vaccination against the human papillomavirus (HPV). We …

Cervical cancer is one of the most prevalent cancers among women worldwide.
Implementation of an HPV-vaccination strategy targeting the major oncogenic types 16 and …

Aim Clinical trials have demonstrated the efficacy of the tetravalent human papillomavirus
(HPV) vaccination in the prevention of cervical cancer and genital warts associated with …

Despite an effective screening programme, 600–700 women are still diagnosed with
cervical cancer in the Netherlands each year. In 2009 a prophylactic vaccine against HPV …

The Dutch Minister of Health, Welfare and Sportintends to implement Human papillomavirus
(HPV) vaccination for 12-year-old girls and catch-up vaccination for 13-16-year-old girls, as …

Objective: Based on positive safety and efficacy data, a quadrivalent Human PapillomaVirus
(HPV) vaccine has been approved in Switzerland to prevent HPV types 6, 11, 16 and 18 …

Background Increasingly, countries have introduced female vaccination against human
papillomavirus (HPV), causally linked to several cancers and genital warts, but few have …